Affiliation:
1. Department of Pharmaceutics, ISF College of Pharmacy, Moga, 142001, India
Abstract
Abstract:
Atopic dermatitis (AD), commonly known as Eczema, is a non-communicable skin condition
that tends to become chronic. The deteriorating immunological abnormalities are marked by mild
to severe erythema, severe itching, and recurrent eczematous lesions. Different pharmacological approaches
are used to treat AD. The problem with commercial topical preparations lies in the limitation
of skin atrophy, systemic side effects, and burning sensation that decreases patient compliance. The
carrier-based system promises to eliminate these shortcomings; thus, a novel approach to treating AD
is required. Liposomes, microemulsions, solid lipid nanoparticles (SLNs), nanoemulsions, etc., have
been developed recently to address this ailment. Despite extensive research in the development method
and various techniques, it has been challenging to demonstrate the commercial feasibility of these carrier-
based systems, which illustrates a gap among the different research areas. Further, different soft
wares and other tools have proliferated among biochemists as part of a cooperative approach to drug
discovery. It is crucial in designing, developing, and analyzing processes in the pharmaceutical industry
and is widely used to reduce costs, accelerate the development of biologically innovative active
ingredients, and shorten the development time. This review sheds light on the compilation of extensive
efforts to combat this disease, the product development processes, commercial products along with
patents in this regard, numerous options for each step of computer-aided drug design, including in silico
pharmacokinetics, pharmacodynamics, and toxicity screening or predictions that are important in
finding the drug-like compounds.
Publisher
Bentham Science Publishers Ltd.
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献